| Postoperative PFS | Postoperative OS | ||||||
---|---|---|---|---|---|---|---|---|
 | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
 | P | P | HR | 95%CI | P | P | HR | 95%CI |
Age (> 60 vs. ≤ 60 years) | 0.307 | - | - | - | 0.81 | - | - | - |
Sex (male vs. female) | 0.280 | - | - | - | 0.262 | - | - | - |
Location of pancreatic tumor (proximal vs. distal) | 0.732 | - | - | - | 0.337 | - | - | - |
Tumor diameter (< 20 vs. ≥ 20 mm) | 0.165 | - | - | - | 0.313 | - | - | - |
Margin (R0 vs. R1 and R2) |  < 0.001 |  < 0.001 | 0.194 | 0.088–0.426 | 0.102 | - | - | - |
LN metastasis (( +) vs. ( −)) | 0.884 | - | - | - | 0.058 | - | - | - |
RECIST (PR and CR vs. SD) | 0.306 | - | - | - | 0.016 | 0.079 | 0.399 | 0.143–1.114 |
Duration of systemic treatment | 0.094 | - | - | - | 0.08 | - | - | - |
TNM staging (0, I and II vs. III and IV) | 0.686 | - | - | - | 0.686 | - | - | - |
UPC (LAPC vs. MPC) | 0.949 | - | - | - | 0.414 | - | - | - |
Postoperative change in CA19-9/CEA level (decrease to normal vs. not normalized) | 0.001 | 0.001 | 0.253 | 0.114–0.560 | 0.013 | 0.071 | 0.405 | 0.152–1.108 |
CAP grading system (0 and 1 vs. 2 and 3) | 0.589 | - | - | - | 0.834 | - | - | - |